116 related articles for article (PubMed ID: 9510497)
21. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
Welters MJ; Maliepaard M; Jacobs-Bergmans AJ; Baan RA; Schellens JH; Ma J; van der Vijgh WJ; Braakhuis BJ; Fichtinger-Schepman AM
Carcinogenesis; 1997 Sep; 18(9):1767-74. PubMed ID: 9328174
[TBL] [Abstract][Full Text] [Related]
22. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
23. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
24. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
25. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
26. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
[TBL] [Abstract][Full Text] [Related]
27. The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Carcinogenesis; 1988 Oct; 9(10):1909-11. PubMed ID: 2458857
[TBL] [Abstract][Full Text] [Related]
28. Novel binding interactions of the DNA fragment d(pGpG) cross-linked by the antitumor active compound tetrakis(mu-carboxylato)dirhodium(II,II).
Chifotides HT; Koshlap KM; Pérez LM; Dunbar KR
J Am Chem Soc; 2003 Sep; 125(35):10714-24. PubMed ID: 12940757
[TBL] [Abstract][Full Text] [Related]
29. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.
Brouwers EE; Tibben MM; Pluim D; Rosing H; Boot H; Cats A; Schellens JH; Beijnen JH
Anal Bioanal Chem; 2008 May; 391(2):577-85. PubMed ID: 18385987
[TBL] [Abstract][Full Text] [Related]
30. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Fichtinger-Schepman AM; van der Veer JL; den Hartog JH; Lohman PH; Reedijk J
Biochemistry; 1985 Jan; 24(3):707-13. PubMed ID: 4039603
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM
Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
33. Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.
Mustonen R; Hietanen P; Leppälä S; Takala M; Hemminki K
Arch Toxicol; 1989; 63(5):361-6. PubMed ID: 2818200
[TBL] [Abstract][Full Text] [Related]
34. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Tilby MJ; Johnson C; Knox RJ; Cordell J; Roberts JJ; Dean CJ
Cancer Res; 1991 Jan; 51(1):123-9. PubMed ID: 1703029
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
36. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
37. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
[TBL] [Abstract][Full Text] [Related]
38. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
Tonda ME; Murry DJ; Rodman JH
Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
[TBL] [Abstract][Full Text] [Related]
39. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
40. DNA topology on an increase in positive writhing number of DNA: conformation changes in the time course of cis-diamminedichloroplatinum(II)-DNA adducts.
Kobayashi S; Nakamura Y; Maehara T; Hamashima H; Sasatsu M; Asano K; Ohishi Y; Tanaka A
Chem Pharm Bull (Tokyo); 2001 Sep; 49(9):1053-60. PubMed ID: 11558585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
